RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
Launched by MEDTRONIC VASCULAR · Jun 28, 2018
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Key Inclusion Criteria
- • Symptomatic coronary artery disease including subjects with chronic stable angina, silent ischemia, and acute coronary syndromes including non-ST elevation and ST-elevation myocardial infarction
- • Subject is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use, and the Declaration of Helsinki
- • Subject requires treatment of a single de novo bifurcated lesion amenable to treatment with Resolute Onyx using the provisional stenting technique
- Exclusion Criteria:
- • Unprotected left main disease
- • Subjects with planned PCI of three vessel disease
- • Planned two stent technique (main branch and side branch) of a bifurcation
- • Subjects with more than one bifurcation lesion
About Medtronic Vascular
Medtronic Vascular is a leading global medical technology company dedicated to transforming patient care through innovative vascular solutions. With a strong focus on advancing minimally invasive therapies, Medtronic Vascular develops cutting-edge devices and therapies aimed at treating a wide range of vascular conditions, including peripheral artery disease, coronary artery disease, and structural heart disorders. Committed to improving outcomes and enhancing quality of life for patients, the company actively engages in clinical trials to evaluate the safety and efficacy of its products. Medtronic Vascular leverages its expertise and extensive research to deliver state-of-the-art technologies that empower healthcare professionals and improve patient experiences worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manhasset, New York, United States
Tallahassee, Florida, United States
Clearwater, Florida, United States
Houston, Texas, United States
Hartford, Connecticut, United States
Green Bay, Wisconsin, United States
La Jolla, California, United States
Genk, , Belgium
New York, New York, United States
Ann Arbor, Michigan, United States
Charlottesville, Virginia, United States
Huntsville, Alabama, United States
Toulouse, , France
Banska Bystrica, , Slovakia
Riverside, California, United States
Gainesville, Florida, United States
Tallahassee, Florida, United States
Marietta, Georgia, United States
Coon Rapids, Minnesota, United States
Minneapolis, Minnesota, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
East Syracuse, New York, United States
New York, New York, United States
Germantown, Tennessee, United States
Charleroi, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials